BHO Expected wait times for access to a disease-modifying Alzheimer’s treatment in England: A modelling study November 6, 2024
BHO Current Capacity for Diagnosing Alzheimer’s Disease in Germany and Implications for Wait Times October 8, 2024
BHO Considerations for widespread implementation of blood‐based biomarkers of Alzheimer’s disease October 6, 2024
BHO Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer’s disease October 1, 2024
BHO Estimates of Current Capacity for Diagnosing Alzheimer’s Disease in Sweden and the Need to Expand Specialist Numbers September 15, 2024
BHO Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatmentsImplications of treatment duration and frequency for value and cost-effective price of Alzheimer treatments July 22, 2024
BHO Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease June 12, 2024
BHO Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration. May 7, 2024
BHO State Department of Motor Vehicles Reporting Mandates of Dementia Diagnoses and Dementia Underdiagnosis April 25, 2024
